The DOI matches its Crossref record; 914 of the 914 references it cites were found in a registry or an index.
Human prostate cancer risk factors
Open accessAbstract
Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with similar likelihood of neoplastic foci found within the prostates of men around the world regardless of diet, occupation, lifestyle, or other factors. Essentially all men with circulating androgens will develop microscopic prostate cancer if they live long enough. This review is a contemporary and comprehensive, literature-based analysis of the putative risk factors for human prostate cancer, and the results were presented at a multidisciplinary consensus conference held in Crystal City, Virginia, in the fall of 2002. The objectives were to evaluate known environmental factors and mechanisms of prostatic carcinogenesis and to identify existing data gaps and future research needs. The review is divided into four sections, including 1) epidemiology (endogenous factors [family history, hormones, race, aging and oxidative stress] and exogenous factors [diet, environmental agents, occupation and other factors, including lifestyle factors]); 2) animal and cell culture models for prediction of human risk (rodent models, transgenic models, mouse reconstitution models, severe combined immunodeficiency syndrome mouse models, canine models, xenograft models, and cell culture models); 3) biomarkers in prostate cancer, most of which have been tested only as predictive factors for patient outcome after treatment rather than as risk factors; and 4) genotoxic and nongenotoxic mechanisms of carcinogenesis. The authors conclude that most of the data regarding risk relies, of necessity, on epidemiologic studies, but animal and cell culture models offer promise in confirming some important findings. The current understanding of biomarkers of disease and risk factors is limited. An understanding of the risk factors for prostate cancer has practical importance for public health research and policy, genetic and nutritional education and chemoprevention, and prevention strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 914
Metallothionein protects DNA from oxidative damage
Chubatsu, L. S., & Meneghini, R. (1993) · Biochemical Journal · doi:10.1042/bj2910193 · Cited by 254
Pathologic progression of autochthonous prostate cancer in the TRAMP model
Gingrich, Jr., Barrios, R., Foster, B., & Greenberg, N. (1999) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500296 · Cited by 253
YU, H., HARRIS, R. E., GAO, Y.-T., GAO, R., & WYNDER, E. L. (1991) · International Journal of Epidemiology · doi:10.1093/ije/20.1.76 · Cited by 252
Dietary Fat and Prostate Cancer: Current Status
Kolonel, L. N., Nomura, A. M. Y., & Cooney, R. V. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.414 · Cited by 251
Steiner, M. S. (1992) · Molecular Endocrinology · doi:10.1210/me.6.1.15 · Cited by 249
Mentor-Marcel, R. A., Lamartiniere, C. A., Eltoum, I.-E. A., Greenberg, N. M., & Elgavish, A. (2001) · PubMed · Cited by 249
Proliferating cell nuclear antigen: More than a clamp for DNA polymerases
Jónsson, Z. O., & Hübscher, U. (1997) · BioEssays · doi:10.1002/bies.950191106 · Cited by 248
Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset
Hardy, D. O. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.12.4400 · Cited by 247
Androgen receptors in prostate cancer.
Culig, Z., Klocker, H., Bartsch, G., & Hobisch, A. (2002) · Endocrine-related cancer · doi:10.1677/erc.0.0090155 · Cited by 247
Epidemiology of prostate cancer
Haas, G. P., & Sakr, W. A. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.5.273 · Cited by 246
Kolonel, L. N. (1996) · Cancer Causes and Control · doi:10.1007/bf00115640 · Cited by 244
Morton, M. S., Chan, P. S. F., Cheng, C., Blacklock, N., Matos-Ferreira, A., Abranches-Monteiro, L., Correia, R., Llyod, S., & Griffiths, K. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970701)32:2<122::aid-pros7>3.0.co;2-o · Cited by 244
Takeda, H., Chodak, G., Mutchnik, S., Nakamoto, T., & Chang, C. (1990) · Journal of Endocrinology · doi:10.1677/joe.0.1260017 · Cited by 243
Epidermal growth factor receptor biology (IMC-C225)
Kim, E. S., Khuri, F. R., & Herbst, R. S. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00014 · Cited by 242
T CELL RECEPTOR GENE DIVERSITY AND SELECTION
Davis, M. M. (1990) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.59.070190.002355 · Cited by 241
Sadi, M. V., Walsh, P. C., & Barrack, E. R. (1991) · Cancer · doi:10.1002/1097-0142(19910615)67:12<3057::aid-cncr2820671221>3.0.co;2-s · Cited by 240
Increase in metallothionein produced by chemicals that induce oxidative stress
Bauman, J. W., Liu, J., Liu, Y. P., & Klaassen, C. D. (1991) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(05)80017-1 · Cited by 239
Phytoestrogen intake and prostate cancer: A case‐control study using a new database
Strom, S. S., Yamamura, Y., Duphorne, C. M., Spitz, M. R., Babaian, R. J., Pillow, P. C., & Hursting, S. D. (1999) · Nutrition and Cancer · doi:10.1080/01635589909514743 · Cited by 239
Case-Control Studies of Prostate Cancer in Blacks and Whites in Southern California
Ross, R. K., Shimizu, H., Paganini‐Hill, A., Honda, G. D., & Henderson, B. E. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/78.5.869 · Cited by 239
The Role of αvβ3 in Prostate Cancer Progression
Cooper, C. R., Chay, C. H., & Pienta, K. J. (2002) · Neoplasia · doi:10.1038/sj.neo.7900224 · Cited by 238
(1996) · PubMed · Cited by 238
Williams, R. R., Stegens, N. L., & Goldsmith, J. R. (1977) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/59.4.1147 · Cited by 238
Superoxide dismutase, aging, and degenerative disease
Warner, H. R. (1994) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)90080-9 · Cited by 238
Cerhan, J. R., Torner, J. C., Lynch, C. F., Rubenstein, L. M., Lemke, J. H., Cohen, M. B., Lubaroff, D. M., & Wallace, R. B. (1997) · Cancer Causes & Control · doi:10.1023/a:1018428531619 · Cited by 238
Mukherjee, P., Sotnikov, A. V., Mangian, H. J., Zhou, J.-R., Visek, W. J., & Clinton, S. K. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.512 · Cited by 237
Telomerase activity: A biomarker of cell proliferation, not malignant transformation
Belair, C. D., Yeager, T. R., Lopez, P. M., & Reznikoff, C. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13677 · Cited by 236
Kanety, H. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.1.229 · Cited by 236
Pietrzkowski, Z. J., Mulholland, G., Gomella, L. G., Jameson, B. A., Wernicke, D., & Baserga, R. (1993) · PubMed · Cited by 236
Wakui, S., Furusato, M., Itoh, T., et al. (1992) · The Journal of Pathology · doi:10.1002/path.1711680303 · Cited by 234
Loss of the chromosomal region 10q23-25 in prostate cancer.
Gray, I. C., Phillips, S. M. A., Lee, S. J., Neoptolemos, J. P., Weissenbach, J., & Spurr, N. K. (1995) · PubMed · Cited by 232
Bonkhoff, H., Stein, U., & REMBERGER, K. (1994) · Human Pathology · doi:10.1016/0046-8177(94)90169-4 · Cited by 232
PLASMA SELENIUM LEVEL BEFORE DIAGNOSIS AND THE RISK OF PROSTATE CANCER DEVELOPMENT
BROOKS, J. D., METTER, E. J., CHAN, D. W., SOKOLL, L. J., LANDIS, P., NELSON, W. G., MULLER, D., ANDRES, R., & CARTER, H. B. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65500-0 · Cited by 231
Androgen-repressed phenotype in human prostate cancer
Zhau, H. Y. E., Chang, S.-M., Chen, B.-Q., Wang, Y., Zhang, H., Kao, C., Sang, Q. A., Pathak, S. J., & Chung, L. W. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15152 · Cited by 231
Nickerson, T., Chang, F., Lorimer, D., Smeekens, S. P., Sawyers, C. L., & Pollak, M. (2001) · PubMed · Cited by 231
Haemodilution in acute stroke: Results of the Italian haemodilution trial
Candelise, L., Colombo, R., Rango, M., Pinardi, G., Fieschi, C., Argentino, C., Giubilei, F., Rasura, M., Cappellari, S., Casazza, A. P., et al. (1988) · The Lancet · Cited by 230
Diet in the Epidemiology of Carcinoma of the Prostate Gland 234
(1983) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/70.4.687 · Cited by 229
Masumori, N., Thomas, T. Z., Chaurand, P., Case, T. C., Paul, M., Kasper, S. F., Caprioli, R. M., Tsukamoto, T., Shappell, S. B., & Matusik, R. J. (2001) · PubMed · Cited by 228
Clinical and Experimental Studies of Benign Prostatic Hyperplasia
Coffey, D. S., & Walsh, P. C. (1990) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00960-5 · Cited by 228
Detailed methylation analysis of the glutathione S-transferase π (GSTP1) gene in prostate cancer
Millar, D. S., Ow, K. K., Paul, C. L., Russell, P. J., Molloy, P. L., & Clark, S. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202415 · Cited by 227
Soy and isoflavone consumption in relation to prostate cancer risk in China.
Lee, M. M., Gomez, S. L., Chang, J. S.-M., Wey, M., Wang, R.-T., & Hsing, A. W. (2003) · PubMed · Cited by 225
CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.
Wainstein, M. A., He, F., Robinson, D. R., Kung, H., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., & Kursh, E. D. (1994) · PubMed · Cited by 225
Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas.
Ramaekers, F. C. S., van Niekerk, C., Poels, L. G., Schaafsma, E., Huijsmans, A., Robben, H., Schaart, G., & VOOIJS, P. G. (1990) · Europe PMC (PubMed Central) · Cited by 224
Zeegers, M. P. A., Jellema, A., & Ostrer, H. (2003) · Cancer · doi:10.1002/cncr.11262 · Cited by 223
Nemeth, J. A. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.1.17 · Cited by 221
Sensibar, J. A., Sutkowski, D. M., Raffo, A. J., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., & Lee, C. (1995) · PubMed · Cited by 219
Getzenberg, R. H., Light, B. W., Lapco, P. E., Konety, B. R., Nangia, A. K., Acierno, J. S., Dhir, R., Shurin, Z., Day, R. S., Trump, D. L., et al. (1997) · Urology · doi:10.1016/s0090-4295(97)00408-1 · Cited by 219
ENDOGENOUS SEX HORMONE LEVELS IN OLDER ADULT MEN WITH DIABETES MELLITUS
BARRETT-CONNOR, E., KHAW, K.-T., & YEN, S. S. C. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115732 · Cited by 217
A prospective study on intake of animal products and risk of prostate cancer
Michaud, D. S., Augustsson, K., Rimm, E. B., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2001) · Cancer Causes & Control · doi:10.1023/a:1011256201044 · Cited by 217
Lee, W. H., Isaacs, W. B., Bova, G. S., & Nelson, W. G. (1997) · PubMed · Cited by 217
Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer.
Gao, X., Zacharek, A., Salkowski, A., Grignon, D. J., Sakr, W., Porter, A. T., & Honn, K. V. (1995) · PubMed · Cited by 215
Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.
Lee, S. O., Lou, W., Hou, M., Miguel, F. D., Gerber, L., & Gao, A. C. (2003) · PubMed · Cited by 215
Familial Patterns of Prostate Cancer: A Case-Control Analysis
Spitz, M. R., Currier, R. D., Fueger, J. J., Babaian, R. J., & Newell, G. R. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)38074-6 · Cited by 215
Shariat, S. F., Shalev, M., Menesses-Diaz, A., Kim, I. Y., Kattan, M. W., Wheeler, T. M., & Slawin, K. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2856 · Cited by 214
Effect of flavonoids on cell cycle progression in prostate cancer cells
Kobayashi, T., Nakata, T., & Kuzumaki, T. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00738-8 · Cited by 214
Scher, H. I., Sarkis, A. S., Reuter, V., Cohen, D., Netto, G. J., Petrylak, D. P., LIANES, P., FUKS, Z. Y., Mendelsohn, J. M., & Cordon‐Cardo, C. (1995) · PubMed · Cited by 214
Iwamura, M., Sluss, P. M., Casamento, J. B., & Cockett, A. T. K. (1993) · The Prostate · doi:10.1002/pros.2990220307 · Cited by 213
Molecular Biology of Metallothionein Gene Expression
Palmiter, R. D. (1987) · Experientia Supplementum · doi:10.1007/978-3-0348-6784-9_4 · Cited by 212
Hayflick, L. (1985) · Experimental Gerontology · doi:10.1016/0531-5565(85)90032-4 · Cited by 211
Lifestyle and Anthropometric Risk Factors for Prostate Cancer in a Cohort of Iowa Men
Putnam, S. D., Cerhan, J. R., Parker, A. S., Bianchi, G. D., Wallace, R. B., Cantor, K. P., & Lynch, C. F. (2000) · Annals of Epidemiology · doi:10.1016/s1047-2797(00)00057-0 · Cited by 210
Serologic Precursors of Cancer. Retinol, Carotenoids, and Tocopherol and Risk of Prostate Cancer
Hsing, A. W., Comstock, G. W., Abbey, H., & Polk, B. F. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.11.941 · Cited by 210
Anthropometry in Relation to Prostate Cancer Risk in the Netherlands Cohort Study
Schuurman, A. G., Goldbohm, R. A., Dorant, E., & van den Brandt, P. A. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010241 · Cited by 208
Hakimi, J. M., Schoenberg, M., Rondinelli, R. H., Piantadosi, S., & Barrack, E. R. (1997) · PubMed · Cited by 206
Dietary fat intake and risk of prostate cancer: A prospective study of 25,708 Norwegian men
Veierød, M. B., Laake, P., & Thelle, D. S. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971127)73:5<634::aid-ijc4>3.0.co;2-y · Cited by 206
Animal cell shape changes and gene expression
Ben‐Ze've, A. (1991) · BioEssays · doi:10.1002/bies.950130502 · Cited by 206
Oka, Y., Rozek, L. M., & Czech, M. P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39385-7 · Cited by 204
Prostate cancer risk and consumption of fish oils: A dietary biomarker-based case–control study
Norrish, A. E., Skeaff, C. M., Arribas, G. L. B., Sharpe, S. J., & Jackson, R. T. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690835 · Cited by 204
Cell–cell interaction in prostate gene regulation and cytodifferentiation
Liu, A. Y., True, L. D., LaTray, L., Nelson, P. S., Ellis, W. J., Vessella, R. L., Lange, P. H., Hood, L., & van den Engh, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10705 · Cited by 202
ras gene mutations in human prostate cancer.
Carter, B. S., Epstein, J. I., & Isaacs, W. B. (1990) · PubMed · Cited by 202
Laniado, M., Lalani, E., Fraser, S. P., Grimes, J. A., Bhangal, G., Djamgoz, M. B. A., & Abel, P. D. (1997) · Europe PMC (PubMed Central) · Cited by 201
Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden
Andersson, S.-O., Wolk, A., Bergström, R., Giovannucci, E., Lindgren, C., Baron, J., & Adami, H.-O. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961211)68:6<716::aid-ijc4>3.0.co;2-6 · Cited by 201
Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)
Chan, J. M., Giovannucci, E., Andersson, S.-O., Yuen, J., Adami, H.-O., & Wolk, A. (1998) · Cancer Causes & Control · doi:10.1023/a:1008823601897 · Cited by 200
Wc, P., Jd, K., Navre, M., Grogan, T., Kittelson, J. M., Rb, N., & Bowden, G. T. (1993) · PubMed · Cited by 200
Chipuk, J. E., Cornelius, S. C., Pultz, N. J., Jorgensen, J. S., Bonham, M. J., Kim, S.-J., & Danielpour, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108855200 · Cited by 200
Comstock, G. W., Bush, T. L., & Helzlsouer, K. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116264 · Cited by 200
Bostwick, D. G., Shan, A., Qian, J., Darson, M. F., Maihle, N. J., Jenkins, R. B., & Liang Cheng, C. (1998) · Cancer · Cited by 199
Self-citationA Retrospective Cohort Study of Vasectomy and Prostate Cancer in US Men
Giovannucci, E. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500070058029 · Cited by 198
Association of energy and fat intake with prostate carcinoma risk
Schuurman, A. G., van den Brandt, P. A., Dorant, E., Brants, H. A. M., & Goldbohm, R. A. (1999) · Cancer · Cited by 198
(1964) · The Lancet · doi:10.1016/s0140-6736(64)90135-7 · Cited by 198
CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13.
Gao, A. C., Lou, W., Dong, J., & Isaacs, J. T. (1997) · PubMed · Cited by 197
Influence of Age and Endocrine Factors on the Volume of Benign Prostatic Hyperplasia
Partin, A. W., Oesterling, J. E., Epstein, J. I., Horton, R., & Walsh, P. C. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)38353-2 · Cited by 196
Androgen receptor gene and hormonal therapy failure of prostate cancer.
Koivisto, P. A., Kolmer, M., Visakorpi, T., & Kallioniemi, O. (1998) · Europe PMC (PubMed Central) · Cited by 196
Leptin Is Associated with Increased Prostate Cancer Risk: A Nested Case-Referent Study1
Stattin, P., Söderberg, S., Hallmans, G., Bylund, A., Kaaks, R., Stenman, U.-H., Bergh, A., & Olsson, T. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7328 · Cited by 196
Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: A hypothesis
Giovannucci, E. (1998) · Cancer Causes & Control · doi:10.1023/a:1008835903714 · Cited by 195
Latil, A., Bièche, I., Pesche, S., Valéri, A., Fournier, G., Cussenot, O., & Lidereau, R. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2<167::aid-ijc11>3.0.co;2-9 · Cited by 195
Eichholzer, M., Stähelin, H. B., Gey, K. F., Lüdin, E., & Bernasconi, F. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960410)66:2<145::aid-ijc1>3.0.co;2-2 · Cited by 195
Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
Umekita, Y., Hiipakka, R. A., Kokontis, J. M., & Liao, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11802 · Cited by 195
Chan, J. M., Stampfer, M. J., Ma, J., Rimm, E. B., Willett, W. C., & Giovannucci, E. L. (1999) · PubMed · Cited by 193
Cher, M. L., Macgrogan, D., Bookstein, R., Brown, J. A., Jenkins, R. B., & Jensen, R. H. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870110304 · Cited by 193
STAMEY, T. A., WARRINGTON, J. A., CALDWELL, M. C., CHEN, Z., FAN, Z., MAHADEVAPPA, M., McNEAL, J. E., NOLLEY, R., & ZHANG, Z. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65528-0 · Cited by 192
Target to apoptosis: A hopeful weapon for prostate cancer
Tang, D. G., & Porter, A. T. (1997) · The Prostate · Cited by 191
Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancers
Buttyan, R., Sawczuk, I. S., Benson, M. C., Siegal, J. D., & Olsson, C. A. (1987) · The Prostate · doi:10.1002/pros.2990110405 · Cited by 191
Target to apoptosis: A hopeful weapon for prostate cancer
Tang, D. G., & Porter, A. T. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970901)32:4<229::aid-pros1>3.0.co;2-e · Cited by 191
Harvei, S., Bjerve, K. S., Tretli, S., Jellum, E., Robsahm, T. E., & VATTEN, L. J. (1997) · International Journal of Cancer · Cited by 190
Denmeade, S. R., Lou, W., Lövgren, J., Malm, J., Lilja, H. G., & Isaacs, J. T. (1997) · PubMed · Cited by 190
Grimes, J. A., Fraser, S. P., Stephens, G. J., Downing, J. E. G., Laniado, M. E., Foster, C. S., Abel, P. D., & Djamgoz, M. B. A. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00772-2 · Cited by 189
Jackson, M. W., Bentel, J. M., & Tilley, W. D. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64774-8 · Cited by 188
An epidemiologic study of mortality within a cohort of rubber workers, 1964-72.
McMichael, A. J., Spirtas, R., & Kupper, L. L. (1974) · PubMed · Cited by 188
Serum selenium and subsequent risk of prostate cancer.
Nomura, A. M. Y., Lee, J., Stemmermann, G. N., & Combs, G. F. (2000) · PubMed · Cited by 187
Knox, J. D., Cress, A. E., Clark, V., Manriquez, L., Affinito, K. S., Dalkin, B. L., & Nagle, R. B. (1994) · PubMed · Cited by 186
Maines, M. D., & Abrahamsson, P.-A. (1996) · Urology · doi:10.1016/s0090-4295(96)00010-6 · Cited by 186
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
Gann, P. H., Ma, J., Hennekens, C. H., Hollis, B. W., Haddad, J. G., & Stampfer, M. J. (1996) · PubMed · Cited by 185
The ?6?1 and ?6?4 integrins in human prostate cancer progression
Cress, A. E., Rabinovitz, I., Zhu, W., & Nagle, R. B. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690293 · Cited by 185
Epidemiological study of prostatic cancer by matched‐pair analysis
Mishina, T., Watanabe, H., Araki, H., & Nakao, M. (1985) · The Prostate · doi:10.1002/pros.2990060411 · Cited by 184
KAUFFMAN, E. C., ROBINSON, V. L., STADLER, W. M., SOKOLOFF, M. H., & RINKER-SCHAEFFER, C. W. (2003) · Journal of Urology · doi:10.1097/01.ju.0000051580.89109.4b · Cited by 184
Chen, C. D., & Sawyers, C. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2862-2870.2002 · Cited by 184
Leav, I., Ho, S.-M., Ofner, P., Merk, F. B., Kwan, P. W.-L., & Damassa, D. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.13.1045 · Cited by 184
Self-citationStromal factors involved in prostate carcinoma metastasis to bone
Cooper, C. R., Chay, C. H., Gendernalik, J. D., Lee, H.-L., Bhatia, J., Taichman, R. S., McCauley, L. K., Keller, E. T., & Pienta, K. J. (2003) · Cancer · doi:10.1002/cncr.11181 · Cited by 184
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
Braun, M. M., Helzlsouer, K. J., Hollis, B. W., & Comstock, G. W. (1995) · Cancer Causes and Control · doi:10.1007/bf00051795 · Cited by 183
Murdoch, A. D., Liu, B., Schwarting, R., Tuan, R. S., & Iozzo, R. V. (1994) · Journal of Histochemistry & Cytochemistry · doi:10.1177/42.2.7507142 · Cited by 182
Basic fibroblast growth factor in human prostate cancer cells.
Nakamoto, T., Chang, C., LI, A. K. C., & Chodak, G. W. (1992) · PubMed · Cited by 182
Establishment and characterization of androgen‐independent human prostate cancer LNCaP cell model
Igawa, T., Lin, F., Lee, M., Karan, D., Batra, S. K., & Lin, M. (2002) · The Prostate · doi:10.1002/pros.10054 · Cited by 181
Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue.
Stearns, M. E., & Wang, M. (1993) · PubMed · Cited by 181
Physical activity on the job and cancer in Missouri.
Brownson, R. C., Chang, J. C., Davis, J. R., & Smith, C. A. (1991) · American Journal of Public Health · doi:10.2105/ajph.81.5.639 · Cited by 180
Physical activity and risk of cancer in middle-aged men
Wannamethee, S. G., Shaper, A. G., & Walker, M. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2096 · Cited by 179
Nutrition, social factors and prostatic cancer in a Northern Italian population
Talamini, R., La Vecchia, C., Decarli, A., Negri, E., & Franceschi, S. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.138 · Cited by 178
Awad, A. B., Fink, C. S., Williams, H., & Kim, U. (2001) · European Journal of Cancer Prevention · doi:10.1097/00008469-200112000-00005 · Cited by 177
(2002) · PubMed · Cited by 175
Gao, J., Arnold, J. T., & Isaacs, J. T. (2001) · PubMed · Cited by 175
Allelic imbalance and microsatellite instability in prostatic adenocarcinoma.
Cunningham, J. M., Shan, A., Wick, M. J., McDonnell, S. K., Schaid, D. J., Tester, D. J., Qian, J., Takahashi, S., Jenkins, R. B., Bostwick, D. G., et al. (1996) · PubMed · Cited by 174
Self-citationGenetic variability of the human SRD5A2 gene: implications for prostate cancer risk.
Reichardt, J. K. V., Makridakis, N. M., Henderson, B. E., Yu, M. C., Pike, M. C., & Ross, R. K. (1995) · PubMed · Cited by 174
Inverse associations between plasma lycopene and other carotenoids and prostate cancer.
Lu, Q., Hung, J. C., Heber, D., Go, V. L. W., Reuter, V. E., Cordon‐Cardo, C., Scher, H. I., Marshall, J., & Zhang, Z. (2001) · PubMed · Cited by 174
Animal products, calcium and protein and prostate cancer risk in the Netherlands Cohort Study
Schuurman, A. G., Brandt, P. A. V. D., Dorant, E., & Goldbohm, R. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690472 · Cited by 174
Bosland, M. C., Ford, H., & Horton, L. (1995) · Carcinogenesis · doi:10.1093/carcin/16.6.1311 · Cited by 174
Smoking and risk of total and fatal prostate cancer in United States health professionals.
Giovannucci, E. L., Rimm, E. B., Ascherio, A., Colditz, G. A., Spiegelman, D. L., Stampfer, M. J., & Willett, W. C. (1999) · PubMed · Cited by 174
Hiatt, R. A., Anne Armstrong, M., Klatsky, A. L., & Sidney, S. (1994) · Cancer Causes & Control · doi:10.1007/bf01830728 · Cited by 173
BCL-2 in prostate cancer: A minireview
Catz, S. D., & Johnson, J. L. (2003) · Apoptosis · doi:10.1023/a:1021692801278 · Cited by 173
Serum micronutrients and prostate cancer in Japanese Americans in Hawaii.
Nomura, A. M. Y., Stemmermann, G. N., Lee, J., & Craft, N. E. (1997) · PubMed · Cited by 173
van Weerden, W. M., de Ridder, C. M., Verdaasdonk, C. L., Romijn, J. C., van der Kwast, T., Schröder, F. H., & van Steenbrugge, G. J. (1996) · Europe PMC (PubMed Central) · Cited by 172
Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas.
Anwar, K., Nakakuki, K., Shiraishi, T., Naiki, H., Yatani, R., & Inuzuka, M. (1992) · PubMed · Cited by 172
Alteration of the Tumor Suppressor Gene p53 in a High Fraction of Hormone Refractory Prostate Cancer
Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W., & Srivastava, S. K. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67065-4 · Cited by 172
IDENTIFICATION OF ANDROSTENEDIONE IN A RIVER CONTAINING PAPER MILL EFFLUENT
Jenkins, R. L., Angus, R. A., McNatt, H., Howell, W. M., Kemppainen, J., KIRK, M. C., & Wilson, E. M. (2001) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5620200622 · Cited by 172
Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam, A. P., Pollak, M., Fillmore, C.-M., Gao, Y.-T., Stanczyk, F. Z., Deng, J., Sesterhenn, I. A., Mostofi, F. K., Fears, T. R., Madigan, M. P., et al. (2001) · PubMed · Cited by 172
HUSMANN, D. A., WILSON, C. M., McPHAUL, M. J., TILLEY, W. D., & WILSON, J. D. (1990) · Endocrinology · doi:10.1210/endo-126-5-2359 · Cited by 171
Jiang, Z., Wu, C.-L., Woda, B. A., Dresser, K., Xu, J., Fanger, G. R., & Yang, X. J. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200209000-00007 · Cited by 171
Borsellino, N., Belldegrun, A. S., & Bonavida, B. (1995) · PubMed · Cited by 171
Isaacs, J. T., Heston, W. D. W., Weissman, R. M., & Coffey, D. S. (1978) · PubMed · Cited by 170
Risk of Uterine Leiomyomata among Premenopausal Women in Relation to Body Size and Cigarette Smoking
Marshall, L. M., Spiegelman, D., Manson, J. E., Goldman, M. B., Barbieri, R. L., Stampfer, M. J., Willett, W. C., & Hunter, D. J. (1998) · Epidemiology · doi:10.1097/00001648-199809000-00007 · Cited by 170
Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate
Fritz, W. A., Wang, J., Eltoum, I.-E., & Lamartiniere, C. A. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00663-3 · Cited by 169
Davies, G., Jiang, W. G., & Mason, M. D. (2001) · PubMed · Cited by 169
Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Bussemakers, M. J. G., van Moorselaar, R. J. A., Giroldi, L. A., Ichikawa, T., Isaacs, J. T., Takeichi, M., Debruyne, F. M. J., & Schalken, J. A. (1992) · PubMed · Cited by 169
Detection and analysis of ?-catenin mutations in prostate cancer
Chesire, D. R., Ewing, C. M., Sauvageot, J., Bova, G. S., & Isaacs, W. B. (2000) · The Prostate · doi:10.1002/1097-0045(20001201)45:4<323::aid-pros7>3.0.co;2-w · Cited by 168
Dietary beta-carotene and cancer of the prostate: a case-control study in Kyoto, Japan.
Ohno, Y., Yoshida, O., Oishi, K., Okada, K., Yamabe, H., & Schroeder, F. H. (1988) · PubMed · Cited by 167
Honda, G., Bernstein, L., Ross, R., Greenland, S., Gerkins, V, & Henderson, B. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.74 · Cited by 167
Smoking and mortality: A prospective study
Weir, J. M., & Dunn, J. E. (1970) · Cancer · doi:10.1002/1097-0142(197001)25:1<105::aid-cncr2820250115>3.0.co;2-z · Cited by 167
Epidemiology of prostatic cancer: A case‐control study
Fincham, S. M., Hill, G. B., Hanson, J., & Wijayasinghe, C. (1990) · The Prostate · doi:10.1002/pros.2990170303 · Cited by 167
Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J. M., Lee, C., & Kozlowski, J. M. (1991) · PubMed · Cited by 167
CIGARETTE SMOKING AND SERUM SEX HORMONES IN MEN
DAI, W. S., GUTAI, J. P., KULLER, L. H., CAULEY, J. A., & FOR THE MRFIT RESEARCH GROUP (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115033 · Cited by 166
STEWART, R. J., PANIGRAHY, D., FLYNN, E., & FOLKMAN, J. (2001) · Journal of Urology · doi:10.1097/00005392-200102000-00095 · Cited by 164
Arai, Y., Mori, T., Suzuki, Y., & Bern, H. A. (1983) · International Review of Cytology · doi:10.1016/s0074-7696(08)61019-0 · Cited by 163
Engeland, A., Andersen, A., Haldorsen, T., & Tretli, S. (1996) · Cancer Causes and Control · doi:10.1007/bf00051881 · Cited by 163
Diabetes mellitus and risk of prostate cancer (United States)
Giovannucci, E. L., Rimm, E. B., Stampfer, M. J., Colditz, G. A., & Willett, W. C. (1998) · Cancer Causes & Control · doi:10.1023/a:1008822917449 · Cited by 162
Impaired prostate tumorigenesis in Egr1-deficient mice
Abdulkadir, S. A., Qu, Z., Garabedian, E., Song, S.-K., Peters, T. J., Svaren, J., Carbone, J. M., Naughton, C. K., Catalona, W. J., Ackerman, J. J. H., et al. (2001) · Nature Medicine · doi:10.1038/83231 · Cited by 162
Nagle, R. B., Hao, J., Knox, J. D., Dalkin, B. L., Clark, V., & Cress, A. E. (1995) · PubMed · Cited by 162
Nomura, A. M. Y., Stemmermann, G. N., Lee, J., Kolonel, L. N., Chen, T. C., Turner, A., & Holick, M. F. (1998) · Cancer Causes & Control · doi:10.1023/a:1008875819232 · Cited by 161
Modugno, F., Weissfeld, J. L., Trump, D. L., Zmuda, J. M., Shea, P., Cauley, J. A., & Ferrell, R. E. (2001) · PubMed · Cited by 161
Nishimura, K. J., Nonomura, N., Satoh, E., Harada, Y., Nakayama, M., Tokizane, T., Fukui, T., Ono, Y., Inoue, H., SHIN, M., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1739 · Cited by 161
Waalkes, M. P., Rehm, S., Riggs, C. W., Bare, R. M., Devor, D. E., Poirier, L. A., Wenk, M. L., Henneman, J. R., & Balaschak, M. S. (1988) · PubMed · Cited by 160
Body size and prostate cancer: a population-based case-control study in China.
Hsing, A. W., Deng, J., Sesterhenn, I. A., Mostofi, F. K., Stanczyk, F. Z., Bénichou, J., Xie, T., & Gao, Y.-T. (2000) · PubMed · Cited by 159
Transplantation of human prostatic carcinoma into nude mice in Matrigel.
Pretlow, T. G., Delmoro, C. M., Dilley, G. G., Spadafora, C. G., & Pretlow, T. P. (1991) · PubMed · Cited by 159
Maramag, C., Menon, M., Balaji, K. C., Reddy, P.-V., & Laxmanan, S. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970801)32:3<188::aid-pros5>3.0.co;2-h · Cited by 158
Thune, I., & Lund, E. (1994) · Cancer Causes & Control · doi:10.1007/bf01831383 · Cited by 158
Thymosin β15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer
Bao, L., Loda, M. F., Janmey, P. A., Stewart, R., Anand‐Apte, B., & Zetter, B. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1322 · Cited by 158
Long-term cancer patient survival in the United States.
Wingo, P. A., Ries, L. A. G., Parker, S. L., & Heath, C. (1998) · PubMed · Cited by 158
Myers, R. B., Srivastava, S., Oelschlager, D. K., & Grizzle, W. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1140 · Cited by 158
Westin, P., Stattin, P., Damber, J., & Bergh, A. R. J. (1995) · Europe PMC (PubMed Central) · Cited by 156
Rise in prostatic Cancer Incidence Associated With Increased Use of Transurethral Resection
Potosky, A. L., Kessier, L., Gridley, G., et al. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.20.1624 · Cited by 156
Miyake, H., Hara, I., Yamanaka, K., Gohji, K., Arakawa, S., & Kamidono, S. (1999) · The Prostate · Cited by 156
A prospective, population-based study of androstenedione, estrogens, and prostatic cancer.
Barrett-Connor, E. L., Garland, C. F., McPhillips, J. B., Khaw, K., & WINGARD, D. L. (1990) · PubMed · Cited by 156
Nutrition and prostate cancer: A case‐control study
Heshmat, M. Y., Kaul, L., Kovi, J., Jackson, M. A., Jackson, A. G., Jones, G. W., Edson, M., Enterline, J. P., Worrell, R. G., & Perry, S. L. (1985) · The Prostate · doi:10.1002/pros.2990060103 · Cited by 155
Magi-Galluzzi, C., Mishra, R., Fiorentino, M., Montironi, R., Yao, H. W., Capodieci, P., Wishnow, K., Kaplan, I. D., Stork, P. A., & Loda, M. F. (1997) · PubMed · Cited by 155
Kang, H., Lin, H., Hu, Y., Yeh, S., Huang, K., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061305498 · Cited by 154
Signal Transduction from N-cadherin Increases Bcl-2
Tran, N. L., Adams, D. G., Vaillancourt, R. R., & Heimark, R. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200300200 · Cited by 154
Xenografts of Primary Human Prostatic Carcinoma
Pretlow, T. G., Wolman, S. R., Micale, M. A., Pelley, R. J., Kursh, E. D., Resnick, M. I., Bodner, D. R., Jacobberger, J. W., Delmoro, C. M., Giaconia, J. M., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.394 · Cited by 154
Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.
Siegall, C. B., Schwab, G., Nordan, R. P., FitzGerald, D. J., & Pastan, I. (1990) · PubMed · Cited by 153
Alcoholism and cancer risk: a population-based cohort study
Adami, H., McLaughlin, J. K., Hsing, A. W., Wolk, A., Ekbom, A., Holmberg, L., & Persson, I. R. (1992) · Cancer Causes & Control · doi:10.1007/bf00051354 · Cited by 153
Bcl-2: an antidote to programmed cell death.
Korsmeyer, S. J. (1992) · PubMed · Cited by 152
Case-control study of diet and prostate cancer in China
Lee, M. M., Wang, R.-T., Hsing, A. W., Gu, F.-L., Wang, T., & Spitz, M. R. (1998) · Cancer Causes & Control · doi:10.1023/a:1008840105531 · Cited by 152
Phillips, S. M. A., Barton, C., Lee, S. J., Morton, D. G., Wallace, D., Lemoine, N. R., & Neoptolemos, J. P. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.482 · Cited by 152
Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival
Edwards, S. M., Badzioch, M. D., Minter, R., Hamoudi, R., Collins, N., Ardern-Jones, A. T., Dowe, A., Osborne, S. A., Kelly, J. A., Shearer, R. J., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991022)84:5<458::aid-ijc2>3.0.co;2-y · Cited by 152
Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.
Ide, H., Yoshida, T., Matsumoto, N., Aoki, K., Osada, Y., Sügimura, T., & Terada, M. (1997) · PubMed · Cited by 152
Vegetable and fruit consumption and prostate cancer risk: a cohort study in The Netherlands.
Schuurman, A. G., Goldbohm, R. A., Dorant, E., & van den Brandt, P. A. (1998) · PubMed · Cited by 152
Foods, nutrients and prostate cancer: a case–control study in Uruguay
Deneo‐Pellegrini, H., Stéfani, E. D., Ronco, Á. L., & Mendilaharsu, M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690396 · Cited by 152
Campbell, C. L., Jiang, Z., Savarese, D. M. F., & Savarese, T. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63940-5 · Cited by 151
Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia
Epstein, J. I., Grignon, D. J., Humphrey, P. A., McNeal, J. E., Sesterhenn, I. A., Troncoso, P., & Wheeler, T. M. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199508000-00002 · Cited by 151
Shariat, S. F., Lamb, D. J., Kattan, M. W., Nguyen, C. V., Kim, J., Beck, J., Wheeler, T. M., & Slawin, K. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.833 · Cited by 151
Winters, S. J., Brufsky, A., Weissfeld, J. L., Trump, D. L., Dyky, M. A., & Hadeed, V. (2001) · Metabolism · doi:10.1053/meta.2001.26714 · Cited by 151
Davis, J. N., Kucuk, O., Djuric, Z., & Sarkar, F. H. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00535-4 · Cited by 150
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt, M., Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G. R., & Moul, J. W. (1996) · PubMed · Cited by 150
DNA-based detection of prostate cancer in urine after prostatic massage
Goessl, C. D., Müller, M., Heicappell, R., et al. (2001) · Urology · doi:10.1016/s0090-4295(01)01268-7 · Cited by 150
The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53
Mashimo, T., Watabe, M., Hirota, S., Hosobe, S., Miura, K., Tegtmeyer, P., Rinker-Schaeffer, C. W., & Watabe, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11307 · Cited by 150
Genetic Susceptibility of Benign Prostatic Hyperplasia
Sanda, M. G., Beaty, T. H., Stutzman, R. E., Childs, B., & Walsh, P. C. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)32831-8 · Cited by 149
Activated ras alleles in human carcinoma of the prostate are rare.
Gumerlock, P. H., Poonamallee, U., Meyers, F. J., & White, R. D. (1991) · PubMed · Cited by 149
A case-control study of cancer of the prostate in Somerset and east Devon
Ewings, P., & Bowie, C. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.418 · Cited by 149
Reed, J. C., Kitada, S., Takayama, S.-I. J., & Miyashita, T. (1994) · Annals of Oncology · doi:10.1093/annonc/5.suppl_1.s61 · Cited by 149
Diet and prostatic cancer: A case‐control study in northern Italy
Talamini, R., Franceschi, S., Vecchia, C. L., Serraino, D., Barra, S., & Negri, E. (1992) · Nutrition and Cancer · doi:10.1080/01635589209514228 · Cited by 148
Harden, S., Guo, Z., Epstein, J. I., & Sidransky, D. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000049627.90307.4d · Cited by 148
Establishment of a New Prostatic Carcinoma Cell Line (TSU-PR1)
Iizumi, T., Yazaki, T., Kanoh, S., Kondo, I., & Koiso, K. (1987) · The Journal of Urology · doi:10.1016/s0022-5347(17)44488-0 · Cited by 148
Early Precursors of Site-Specific Cancers in College Men and Women 2
Whittemore, A. S., Paffenbarger, R. S., Anderson, K. M., & Lee, J. E. (1985) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/74.1.43 · Cited by 147
Kyprianou, N., King, E. D., Bradbury, D., & Rhee, J. G. (1997) · International Journal of Cancer · Cited by 147
Waalkes, M. P., & Rehm, S. (1994) · Journal of Toxicology and Environmental Health · doi:10.1080/15287399409531920 · Cited by 147
Research works printed but not linked: 902
- Oishi, 1995, Cancer Surv., 23, 267
- Parkin, 1992, IARC Sci Publ., 120, 45
- Doherty, 1996, Br J Hosp Med., 55, 104
- Morrison, 1995, Can J Public Health., 86, 274
- Dijkman, 1996, Eur Urol., 30, 281, 10.1159/000474185 · doi:10.1159/000474185
- Wingo, 1998, Cancer Epidemiol Biomarkers Prev., 7, 271
- Merrill, 1996, J Natl Cancer Inst., 88, 1683, 10.1093/jnci/88.22.1683 · doi:10.1093/jnci/88.22.1683
- Mettlin, 1996, Cancer., 77, 150, 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19960101)77:1<150::aid-cncr25>3.0.co;2-3
- Brawley, 1997, Cancer., 80, 1857, 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19971101)80:9<1857::aid-cncr26>3.0.co;2-3
- Wingo, 1997, Cancer., 80, 1810, 10.1002/(SICI)1097-0142(19971101)80:9<1810::AID-CNCR19>3.0.CO;2-8 · doi:10.1002/(sici)1097-0142(19971101)80:9<1810::aid-cncr19>3.0.co;2-8
- Levy, 1993, CMAJ., 149, 617
- Smart, 1997, CA Cancer J Clin., 47, 134, 10.3322/canjclin.47.3.134 · doi:10.3322/canjclin.47.3.134
- Pienta, 1995, Urology., 45, 93, 10.1016/S0090-4295(95)96996-9 · doi:10.1016/s0090-4295(95)96996-9
- Dhom, 1983, J Cancer Res Clin Oncol., 106, 210, 10.1007/BF00402610 · doi:10.1007/bf00402610
- Polednak, 1997, Cancer., 79, 99, 10.1002/(SICI)1097-0142(19970101)79:1<99::AID-CNCR14>3.0.CO;2-1 · doi:10.1002/(sici)1097-0142(19970101)79:1<99::aid-cncr14>3.0.co;2-1
- Newman, 1996, Radiol Technol., 68, 39
- Bostwick, 1992, Cancer., 70, 291, 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4 · doi:10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4
- Partin, 1994, Urology., 44, 646, 10.1016/S0090-4295(94)80197-5 · doi:10.1016/s0090-4295(94)80197-5
- Bostwick, 2000, Curr Urol Rep., 1, 65, 10.1007/s11934-000-0037-x · doi:10.1007/s11934-000-0037-x
- Bostwick, 1987, Cancer., 59, 788, 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I · doi:10.1002/1097-0142(19870215)59:4<788::aid-cncr2820590421>3.0.co;2-i
- Montironi, 1996, Eur Urol., 30, 133, 10.1159/000474162 · doi:10.1159/000474162
- Allam, 1996, Mod Pathol., 9, 742
- Qian, 1997, Hum Pathol., 28, 143, 10.1016/S0046-8177(97)90097-6 · doi:10.1016/s0046-8177(97)90097-6
- Feneley, 1997, Prostate Cancer Prostatic Dis., 1, 79, 10.1038/sj.pcan.4500210 · doi:10.1038/sj.pcan.4500210
- Sakr, 1997, Eur Urol., 32, 15
- Keetch, 1995, J Urol., 154, 347, 10.1016/S0022-5347(01)67044-7 · doi:10.1016/s0022-5347(01)67044-7
- Raviv, 1996, Acta Urol Belgium., 64, 11
- Rovner, 1997, J Urol., 158, 138, 10.1097/00005392-199707000-00042 · doi:10.1097/00005392-199707000-00042
- Davidson, 1995, J Urol., 154, 1295, 10.1016/S0022-5347(01)66840-X · doi:10.1016/s0022-5347(01)66840-x
- Shepherd, 1996, J Urol., 156, 460, 10.1016/S0022-5347(01)65881-6 · doi:10.1016/s0022-5347(01)65881-6
- Langer, 1996, J Urol., 155, 228, 10.1016/S0022-5347(01)66601-1 · doi:10.1016/s0022-5347(01)66601-1
- Bostwick, 1996, Eur Urol., 30, 145, 10.1159/000474164 · doi:10.1159/000474164
- Bostwick, 1996, Cancer., 78, 330, 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W · doi:10.1002/(sici)1097-0142(19960715)78:2<330::aid-cncr22>3.0.co;2-w
- Ferguson, 1994, Urology., 44, 91, 10.1016/S0090-4295(94)80015-4 · doi:10.1016/s0090-4295(94)80015-4
- Aquilina, 1997, J Natl Cancer Inst., 89, 689, 10.1093/jnci/89.10.689 · doi:10.1093/jnci/89.10.689
- Colombel, 1993, Am J Pathol., 143, 390
- Goldstein, 1995, Hum Pathol., 26, 887, 10.1016/0046-8177(95)90012-8 · doi:10.1016/0046-8177(95)90012-8
- Saez, 1998, Mod Pathol., 11, 1193
- Papadopoulos, 2001, Clin Cancer Res., 7, 1533
- Kirschenbaum, 1999, Mol Urol., 3, 163
- Molberg, 1994, Am J Clin Pathol., 101, 266, 10.1093/ajcp/101.3.266 · doi:10.1093/ajcp/101.3.266
- Shah, 2001, Arch Pathol Lab Med., 125, 141, 10.5858/2001-125-0141-HAHCOS · doi:10.5858/2001-125-0141-hahcos
- Bostwick, 1995, Arch Pathol Lab Med., 119, 444
- Varma, 2002, Arch Pathol Lab Med., 126, 554, 10.5858/2002-126-0554-MCFTDO · doi:10.5858/2002-126-0554-mcftdo
- Egan, 1997, Am J Surg Pathol., 21, 931, 10.1097/00000478-199708000-00007 · doi:10.1097/00000478-199708000-00007
- Zhou, 2001, Am J Clin Pathol., 115, 39, 10.1309/2APJ-YKBD-97EH-67GW · doi:10.1309/2apj-ykbd-97eh-67gw
- Bonin, 1997, Cancer., 79, 75, 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19970101)79:1<75::aid-cncr11>3.0.co;2-3
- Ozcan, 2001, Eur Urol., 40, 308, 10.1159/000049791 · doi:10.1159/000049791
- D'Amico, 2001, J Urol., 165, 126, 10.1097/00005392-200101000-00031 · doi:10.1097/00005392-200101000-00031
- Nelson, 2002, Urology., 59, 740, 10.1016/S0090-4295(02)01654-0 · doi:10.1016/s0090-4295(02)01654-0
- O'Malley, 2002, Urology., 59, 85, 10.1016/S0090-4295(01)01486-8 · doi:10.1016/s0090-4295(01)01486-8
- Freedland, 2002, J Urol., 167, 516, 10.1016/S0022-5347(01)69076-1 · doi:10.1016/s0022-5347(01)69076-1
- Sebo, 2001, Cancer., 91, 2196, 10.1002/1097-0142(20010601)91:11<2196::AID-CNCR1249>3.0.CO;2-# · doi:10.1002/1097-0142(20010601)91:11<2196::aid-cncr1249>3.0.co;2-#
- Merrick, 2002, Cancer J., 8, 79, 10.1097/00130404-200201000-00014 · doi:10.1097/00130404-200201000-00014
- Bahnson, 1989, Prostate., 15, 149, 10.1002/pros.2990150208 · doi:10.1002/pros.2990150208
- Montironi, 1993, Virchows Arch A Pathol Anat Histopathol., 422, 185, 10.1007/BF01621801 · doi:10.1007/bf01621801
- Weidner, 1993, Am J Pathol., 143, 401
- Brawer, 1994, Cancer., 73, 678, 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO;2-6 · doi:10.1002/1097-0142(19940201)73:3<678::aid-cncr2820730329>3.0.co;2-6
- Hall, 1994, Urology., 44, 869, 10.1016/S0090-4295(94)80173-8 · doi:10.1016/s0090-4295(94)80173-8
- Vesalainen, 1994, Anticancer Res., 14, 709
- Epstein, 2000, Urology., 56, 283, 10.1016/S0090-4295(00)00640-3 · doi:10.1016/s0090-4295(00)00640-3
- Silberman, 1997, Cancer., 79, 772, 10.1002/(SICI)1097-0142(19970215)79:4<772::AID-CNCR14>3.0.CO;2-X · doi:10.1002/(sici)1097-0142(19970215)79:4<772::aid-cncr14>3.0.co;2-x
- de la Taille, 2000, Am J Clin Pathol., 113, 555, 10.1309/02W2-KE50-PKEF-G2G4 · doi:10.1309/02w2-ke50-pkef-g2g4
- Stamey, 1999, JAMA., 281, 1395, 10.1001/jama.281.15.1395 · doi:10.1001/jama.281.15.1395
- van den Ouden, 1998, Urol Int., 60, 17, 10.1159/000030197 · doi:10.1159/000030197
- McNeal, 1996, Am J Surg Pathol., 20, 1351, 10.1097/00000478-199611000-00006 · doi:10.1097/00000478-199611000-00006
- Mehta, 2001, Clin Cancer Res., 7, 81
- Whittemore, 1995, Am J Epidemiol., 141, 732, 10.1093/oxfordjournals.aje.a117495 · doi:10.1093/oxfordjournals.aje.a117495
- Klein, 1998, Prostate Cancer Prostatic Dis., 1, 297, 10.1038/sj.pcan.4500257 · DOI
- Damber, 1998, Int J Cancer., 78, 293, 10.1002/(SICI)1097-0215(19981029)78:3<293::AID-IJC5>3.0.CO;2-Q · doi:10.1002/(sici)1097-0215(19981029)78:3<293::aid-ijc5>3.0.co;2-q
- Bratt, 1999, Eur J Cancer., 35, 272, 10.1016/S0959-8049(98)00358-X · doi:10.1016/s0959-8049(98)00358-x
- Cerhan, 1999, Cancer Epidemiol Biomarkers Prev., 8, 53
- Lightfoot, 2000, Ann Epidemiol., 10, 470, 10.1016/S1047-2797(00)00112-5 · doi:10.1016/s1047-2797(00)00112-5
- Kalish, 2000, Urology., 56, 803, 10.1016/S0090-4295(00)00780-9 · DOI
- Kotsis, 2002, J Urol., 167, 1659, 10.1016/S0022-5347(05)65173-7 · doi:10.1016/s0022-5347(05)65173-7
- Cotter, 2002, Prostate., 50, 216, 10.1002/pros.10051 · doi:10.1002/pros.10051
- Stone, 2003, Ethn Dis., 13, 233
- Gronberg, 1999, Cancer., 86, 477, 10.1002/(SICI)1097-0142(19990801)86:3<477::AID-CNCR16>3.0.CO;2-K · doi:10.1002/(sici)1097-0142(19990801)86:3<477::aid-cncr16>3.0.co;2-k
- Schuurman, 1999, Epidemiology., 10, 192, 10.1097/00001648-199903000-00020 · doi:10.1097/00001648-199903000-00020
- McLellan, 1995, CMAJ., 153, 895
- Staples, 2003, Cancer Causes Control., 14, 161, 10.1023/A:1023073203467 · doi:10.1023/a:1023073203467
- Matikainen, 1999, Clin Cancer Res., 5, 1275
- Thiessen, 1974, Cancer., 34, 1102, 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5 · doi:10.1002/1097-0142(197410)34:4<1102::aid-cncr2820340421>3.0.co;2-5
- Anderson, 1992, J Natl Cancer Inst., 84, 1114, 10.1093/jnci/84.14.1114 · doi:10.1093/jnci/84.14.1114
- Andrieu, 1991, Eur J Cancer., 27, 244, 10.1016/0277-5379(91)90506-9 · doi:10.1016/0277-5379(91)90506-9
- Henderson, 1982, Cancer Res., 42, 3232
- Ghanadian, 1979, Br J Cancer., 39, 696, 10.1038/bjc.1979.122 · doi:10.1038/bjc.1979.122
- Vatten, 1997, Cancer Epidemiol Biomarkers Prev., 6, 967
- Nomura, 1996, Cancer Epidemiol Biomarkers Prev., 5, 621
- Guess, 1997, Cancer Epidemiol Biomarkers Prev., 6, 21
- Chang, 2001, Prostate., 46, 62, 10.1002/1097-0045(200101)46:1<62::AID-PROS1009>3.0.CO;2-V · doi:10.1002/1097-0045(200101)46:1<62::aid-pros1009>3.0.co;2-v
- Stattin, 2001, J Clin Endocrinol Metab., 86, 1341
- Ross, 1986, J Natl Cancer Inst., 76, 45
- Barrett-Connor, 1990, Cancer Res., 50, 169
- Jackson, 1981, Progr Clin Biol Res., 53, 111
- Modugno, 2001, Clin Cancer Res., 7, 3092
- Haenszel, 1968, J Natl Cancer Inst., 40, 43
- Locke, 1980, J Natl Cancer Inst., 65, 1149
- Stellman, 1994, Cancer., 73, 1270, 10.1002/1097-0142(19940215)73:4<1270::AID-CNCR2820730423>3.0.CO;2-Y · doi:10.1002/1097-0142(19940215)73:4<1270::aid-cncr2820730423>3.0.co;2-y
- Merrill, 2000, Urology., 55, 730, 10.1016/S0090-4295(99)00564-6 · doi:10.1016/s0090-4295(99)00564-6
- Abdalla, 1998, Semin Urol Oncol., 16, 207
- Asbell, 2000, J Natl Med Assoc., 92, 445
- Zhang, 2000, J Urol., 163, 131, 10.1016/S0022-5347(05)67988-8 · doi:10.1016/s0022-5347(05)67988-8
- Fowler, 2000, J Urol., 163, 1467, 10.1016/S0022-5347(05)67644-6 · doi:10.1016/s0022-5347(05)67644-6
- Wu, 2001, Cancer Epidemiol Biomarkers Prev., 10, 533
- Reichardt, 1995, Cancer Res., 55, 3973
- Platz, 1999, Cancer Epidemiol Biomarkers Prev., 8, 1107
- Winter, 2001, Urology., 58, 614, 10.1016/S0090-4295(01)01273-0 · doi:10.1016/s0090-4295(01)01273-0
- Ekman, 1999, Prostate., 39, 262, 10.1002/(SICI)1097-0045(19990601)39:4<262::AID-PROS6>3.0.CO;2-P · doi:10.1002/(sici)1097-0045(19990601)39:4<262::aid-pros6>3.0.co;2-p
- Corder, 1995, Cancer Epidemiol Biomarkers Prev., 4, 655
- Yamada, 2001, Int J Cancer., 92, 683, 10.1002/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4 · doi:10.1002/1097-0215(20010601)92:5<683::aid-ijc1255>3.0.co;2-4
- Leadon, 1990, Health Phys., 59, 15, 10.1097/00004032-199007000-00001 · doi:10.1097/00004032-199007000-00001
- Statland, 1992, Clin Chem., 38, 1587
- Palmiter, 1987, Experientia., 52, 63
- Yu, 1994, Cancer., 73, 596, 10.1002/1097-0142(19940201)73:3<596::AID-CNCR2820730316>3.0.CO;2-N · doi:10.1002/1097-0142(19940201)73:3<596::aid-cncr2820730316>3.0.co;2-n
- Hietanen, 1994, Eur J Clin Nutr., 48, 575
- Hietanen, 1991, Carcinogenesis., 12, 591, 10.1093/carcin/12.4.591 · doi:10.1093/carcin/12.4.591
- Clark, 1996, JAMA., 276, 1957, 10.1001/jama.1996.03540240035027 · DOI · Paper page
- Han, 1995, Carcinogenesis., 16, 951, 10.1093/carcin/16.4.951 · doi:10.1093/carcin/16.4.951
- Schuurman, 1999, Cancer., 86, 1019, 10.1002/(SICI)1097-0142(19990915)86:6<1019::AID-CNCR18>3.0.CO;2-H · doi:10.1002/(sici)1097-0142(19990915)86:6<1019::aid-cncr18>3.0.co;2-h
- Berg, 1975, Cancer Res., 35, 3345
- Blair, 1978, J Natl Cancer Inst., 61, 1379
- Ohno, 1988, Cancer Res., 48, 1331
- Mettlin, 1989, Cancer., 64, 605, 10.1002/1097-0142(19890801)64:3<605::AID-CNCR2820640307>3.0.CO;2-I · doi:10.1002/1097-0142(19890801)64:3<605::aid-cncr2820640307>3.0.co;2-i
- Hayes, 1999, Cancer Epidemiol Biomarkers Prev., 8, 25
- Graham, 1983, J Natl Cancer Inst., 70, 687
- Ross, 1987, J Natl Cancer Inst., 78, 869
- Severson, 1989, Cancer Res., 49, 1857
- Mills, 1989, Cancer., 64, 598, 10.1002/1097-0142(19890801)64:3<598::AID-CNCR2820640306>3.0.CO;2-6 · doi:10.1002/1097-0142(19890801)64:3<598::aid-cncr2820640306>3.0.co;2-6
- Hirayama, 1979, Natl Cancer Inst Monogr., 53, 149
- Hsing, 1990, Cancer Res., 50, 6836
- De Stefani, 2000, Cancer Epidemiol Biomarkers Prev., 9, 335
- Harvei, 1997, Int J Cancer., 71, 545, 10.1002/(SICI)1097-0215(19970516)71:4<545::AID-IJC7>3.0.CO;2-U · doi:10.1002/(sici)1097-0215(19970516)71:4<545::aid-ijc7>3.0.co;2-u
- Bishop, 1988, Immunogenetics., 28, 184, 10.1007/BF00375858 · doi:10.1007/bf00375858
- Sporn, 1984, J Natl Cancer Inst., 73, 1381
- Kummet, 1983, Semin Oncol., 10, 281
- Olsen, 1996, Ugeskr Laeger., 158, 3171
- Kolonel, 1987, Cancer Res., 47, 2982
- Ellison, 1998, Chron Dis Can., 19, 1
- Paganini-Hill, 1987, J Natl Cancer Inst., 79, 443
- Hayes, 1988, Cancer., 62, 2021, 10.1002/1097-0142(19881101)62:9<2021::AID-CNCR2820620925>3.0.CO;2-R · doi:10.1002/1097-0142(19881101)62:9<2021::aid-cncr2820620925>3.0.co;2-r
- Reichman, 1990, Cancer Res., 50, 2311
- Wald, 1986, Br J Cancer., 54, 957, 10.1038/bjc.1986.267 · doi:10.1038/bjc.1986.267
- Nomura, 1997, Cancer Epidemiol Biomarkers Prev., 6, 487
- Cook, 1999, Cancer., 86, 1783, 10.1002/(SICI)1097-0142(19991101)86:9<1783::AID-CNCR21>3.0.CO;2-N · doi:10.1002/(sici)1097-0142(19991101)86:9<1783::aid-cncr21>3.0.co;2-n
- Lu, 2001, Cancer Epidemiol Biomarkers Prev., 10, 749
- Hirayama, 1986, Gan No Rinsho., 32, 610
- Clinton, 1999, Cancer., 86, 1629, 10.1002/(SICI)1097-0142(19991101)86:9<1629::AID-CNCR1>3.0.CO;2-4 · doi:10.1002/(sici)1097-0142(19991101)86:9<1629::aid-cncr1>3.0.co;2-4
- Eichholzer, 1999, Prostate., 38, 189, 10.1002/(SICI)1097-0045(19990215)38:3<189::AID-PROS3>3.0.CO;2-N · doi:10.1002/(sici)1097-0045(19990215)38:3<189::aid-pros3>3.0.co;2-n
- Schwartz, 1990, Anticancer Res., 10, 1307
- Corder, 1993, Cancer Epidemiol Biomarkers Prev., 2, 467
- Peehl, 1999, Eur Urol., 35, 392, 10.1159/000019914 · doi:10.1159/000019914
- Suzuki, 2003, Int J Urol., 10, 261, 10.1046/j.1442-2042.2003.00617.x · doi:10.1046/j.1442-2042.2003.00617.x
- Schwartz, 1998, Cancer Epidemiol Biomarkers Prev., 7, 391
- Gann, 1996, Cancer Epidemiol Biomarkers Prev., 5, 121
- Schwartz, 1994, Anticancer Res., 14, 1077
- Chan, 1999, Cancer Epidemiol Biomarkers Prev., 8, 893
- Liang, 1999, Prostate., 40, 200, 10.1002/(SICI)1097-0045(19990801)40:3<200::AID-PROS8>3.0.CO;2-3 · doi:10.1002/(sici)1097-0045(19990801)40:3<200::aid-pros8>3.0.co;2-3
- Feustel, 1986, Prostate., 8, 75, 10.1002/pros.2990080109 · doi:10.1002/pros.2990080109
- Leake, 1984, Acta Endocrinol (Copenhagen)., 105, 281, 10.1530/acta.0.1050281 · doi:10.1530/acta.0.1050281
- Whelan, 1983, Br J Urol., 55, 525, 10.1111/j.1464-410X.1983.tb03362.x · doi:10.1111/j.1464-410x.1983.tb03362.x
- Chirulescu, 1987, Med Interne., 25, 257
- Ogunlewe, 1989, Cancer., 63, 1388, 10.1002/1097-0142(19890401)63:7<1388::AID-CNCR2820630725>3.0.CO;2-M · doi:10.1002/1097-0142(19890401)63:7<1388::aid-cncr2820630725>3.0.co;2-m
- Lekili, 1991, Int Urol Nephrol., 23, 151, 10.1007/BF02549712 · doi:10.1007/bf02549712
- McCallum, 1988, Br J Urol., 62, 565, 10.1111/j.1464-410X.1988.tb04427.x · doi:10.1111/j.1464-410x.1988.tb04427.x
- Feustel, 1989, Urol Res., 17, 41
- Tvedt, 1989, Prostate., 15, 41, 10.1002/pros.2990150105 · doi:10.1002/pros.2990150105
- Elghany, 1990, Epidemiology., 1, 107, 10.1097/00001648-199003000-00005 · doi:10.1097/00001648-199003000-00005
- Goodman, 2001, Cancer Epidemiol Biomarkers Prev., 10, 1069
- Nomura, 2000, Cancer Epidemiol Biomarkers Prev., 9, 883
- Grant, 1999, Altern Med Rev., 4, 162
- Rodriguez, 2003, Cancer Epidemiol Biomarkers Prev., 12, 597
- Balaji, 2001, Prostate., 48, 265, 10.1002/pros.1106 · doi:10.1002/pros.1106
- Sung, 1999, Cancer., 86, 484, 10.1002/(SICI)1097-0142(19990801)86:3<484::AID-CNCR17>3.0.CO;2-P · doi:10.1002/(sici)1097-0142(19990801)86:3<484::aid-cncr17>3.0.co;2-p
- Hsieh, 1999, Int J Cancer., 80, 699, 10.1002/(SICI)1097-0215(19990301)80:5<699::AID-IJC12>3.0.CO;2-7 · doi:10.1002/(sici)1097-0215(19990301)80:5<699::aid-ijc12>3.0.co;2-7
- van der Gulden, 1994, Br J Urol., 73, 382, 10.1111/j.1464-410X.1994.tb07601.x · doi:10.1111/j.1464-410x.1994.tb07601.x
- Kolonel, 1977, Lancet., 2, 566, 10.1016/S0140-6736(77)90714-0 · doi:10.1016/s0140-6736(77)90714-0
- Schuman, 1977, Cancer Treat Rep., 61, 181
- Niijima, 1980, Scand J Urol Nephrol., 55, 177
- Newell, 1998, Vet Radiol Ultrasound., 39, 332, 10.1111/j.1740-8261.1998.tb01616.x · doi:10.1111/j.1740-8261.1998.tb01616.x
- Talamini, 1993, Prev Med., 22, 400, 10.1006/pmed.1993.1033 · doi:10.1006/pmed.1993.1033
- Hayes, 1994, Cancer Causes Control., 5, 221, 10.1007/BF01830240 · doi:10.1007/bf01830240
- Lumey, 1997, Prostate., 33, 195, 10.1002/(SICI)1097-0045(19971101)33:3<195::AID-PROS8>3.0.CO;2-I · doi:10.1002/(sici)1097-0045(19971101)33:3<195::aid-pros8>3.0.co;2-i
- Giles, 2001, Ann Oncol., 12, 761, 10.1023/A:1011131105617 · doi:10.1023/a:1011131105617
- Plaskon, 2003, Cancer Epidemiol Biomarkers Prev., 12, 604
- Lotufo, 2000, Int J Cancer., 87, 141, 10.1002/1097-0215(20000701)87:1<141::AID-IJC21>3.0.CO;2-A · doi:10.1002/1097-0215(20000701)87:1<141::aid-ijc21>3.0.co;2-a
- Whittemore, 1985, J Natl Cancer Inst., 74, 43
- Carstensen, 1987, J Epidemiol Commun Health., 41, 166, 10.1136/jech.41.2.166 · DOI
- Giovannucci, 1999, Cancer Epidemiol Biomarkers Prev., 8, 277
- Colditz, 1996, Cancer Causes Control., 7, 560, 10.1007/BF00051890 · doi:10.1007/bf00051890
- Yu, 1997, Cancer Detect Prev., 21, 497
- Verhoeven, 1996, Cancer Epidemiol Biomarkers Prev., 5, 733
- Schuurman, 1998, Cancer Epidemiol Biomarkers Prev., 7, 673
- Kolonel, 2000, Cancer Epidemiol Biomarkers Prev., 9, 795
- Lee, 2003, Cancer Epidemiol Biomarkers Prev., 12, 665
- Gann, 1999, Cancer Res., 59, 1225
- Clinton, 1996, Cancer Epidemiol Biomarkers Prev., 5, 823
- Imaida, 2001, Carcinogenesis., 22, 467, 10.1093/carcin/22.3.467 · doi:10.1093/carcin/22.3.467
- Watson, 1995, Environ Health Perspect., 103, 41
- Soto, 1995, Environ Health Perspect., 103, 113
200 of 902 shown
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Hormones, E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm323 · Cited by 786
Tang, W.-Y., Morey, L. M., Cheung, Y. Y., Birch, L., Prins, G. S., & Ho, S.-M. (2012) · Endocrinology · doi:10.1210/en.2011-1308 · Cited by 164
Self-citationBarrington, W. E., Schenk, J. M., Etzioni, R., Arnold, K. B., Neuhouser, M. L., Thompson, I. M., Lucia, M. S., & Kristal, A. R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0513 · Cited by 107
Metadata
- Authors
- Bostwick, D. G., Burke, H. B., Djakiew, D., Euling, S., Ho, S.-M., Landolph, J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D. J., & Timms, B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004
- Volume
- 101
- Issue
- S10
- Pages
- 2371-2490
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2121518362
- Cited by
- 650
- References
- 914
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4261 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.